Marie Thibault
Stock Analyst at BTIG
(3.20)
# 1,012
Out of 5,134 analysts
112
Total ratings
42.06%
Success rate
3.85%
Average return
Main Sectors:
Stocks Rated by Marie Thibault
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MASI Masimo | Downgrades: Neutral | n/a | $175.55 | - | 8 | Feb 18, 2026 | |
| ATRC AtriCure | Reiterates: Buy | $54 | $32.76 | +64.84% | 8 | Feb 18, 2026 | |
| DXCM DexCom | Reiterates: Buy | $85 | $72.24 | +17.66% | 9 | Feb 13, 2026 | |
| OM Outset Medical | Maintains: Buy | $17 → $15 | $3.47 | +332.28% | 3 | Feb 12, 2026 | |
| EW Edwards Lifesciences | Reiterates: Buy | $103 | $78.54 | +31.14% | 3 | Feb 11, 2026 | |
| BSX Boston Scientific | Reiterates: Buy | $110 | $76.05 | +44.64% | 16 | Feb 9, 2026 | |
| EMBC Embecta | Reiterates: Buy | $25 | $10.40 | +140.50% | 4 | Feb 6, 2026 | |
| HAE Haemonetics | Reiterates: Buy | $88 | $60.51 | +45.44% | 5 | Feb 6, 2026 | |
| ARAY Accuray | Maintains: Buy | $4 → $2 | $0.53 | +276.65% | 3 | Feb 5, 2026 | |
| CBLL CeriBell | Reiterates: Buy | $30 | $19.78 | +51.67% | 2 | Jan 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $145 → $140 | $112.81 | +24.10% | 15 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $370 → $380 | $258.72 | +46.88% | 6 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $32 | $25.07 | +27.64% | 1 | Nov 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $23 | $9.49 | +142.49% | 4 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $195 → $215 | $155.62 | +38.16% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $4.06 | - | 2 | Aug 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $62 → $65 | $75.03 | -13.37% | 8 | Oct 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.08 | - | 2 | Jun 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.45 | - | 3 | Oct 13, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.94 | - | 1 | Jan 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $11 → $6 | $411.10 | -98.54% | 1 | Apr 9, 2020 |
Masimo
Feb 18, 2026
Downgrades: Neutral
Price Target: n/a
Current: $175.55
Upside: -
AtriCure
Feb 18, 2026
Reiterates: Buy
Price Target: $54
Current: $32.76
Upside: +64.84%
DexCom
Feb 13, 2026
Reiterates: Buy
Price Target: $85
Current: $72.24
Upside: +17.66%
Outset Medical
Feb 12, 2026
Maintains: Buy
Price Target: $17 → $15
Current: $3.47
Upside: +332.28%
Edwards Lifesciences
Feb 11, 2026
Reiterates: Buy
Price Target: $103
Current: $78.54
Upside: +31.14%
Boston Scientific
Feb 9, 2026
Reiterates: Buy
Price Target: $110
Current: $76.05
Upside: +44.64%
Embecta
Feb 6, 2026
Reiterates: Buy
Price Target: $25
Current: $10.40
Upside: +140.50%
Haemonetics
Feb 6, 2026
Reiterates: Buy
Price Target: $88
Current: $60.51
Upside: +45.44%
Accuray
Feb 5, 2026
Maintains: Buy
Price Target: $4 → $2
Current: $0.53
Upside: +276.65%
CeriBell
Jan 28, 2026
Reiterates: Buy
Price Target: $30
Current: $19.78
Upside: +51.67%
Jan 23, 2026
Maintains: Buy
Price Target: $145 → $140
Current: $112.81
Upside: +24.10%
Nov 21, 2025
Maintains: Buy
Price Target: $370 → $380
Current: $258.72
Upside: +46.88%
Nov 18, 2025
Initiates: Buy
Price Target: $32
Current: $25.07
Upside: +27.64%
Nov 4, 2025
Reiterates: Buy
Price Target: $23
Current: $9.49
Upside: +142.49%
Oct 31, 2025
Maintains: Buy
Price Target: $195 → $215
Current: $155.62
Upside: +38.16%
Aug 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $4.06
Upside: -
Oct 14, 2024
Maintains: Buy
Price Target: $62 → $65
Current: $75.03
Upside: -13.37%
Jun 25, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.08
Upside: -
Oct 13, 2021
Downgrades: Neutral
Price Target: n/a
Current: $1.45
Upside: -
Jan 21, 2021
Downgrades: Neutral
Price Target: n/a
Current: $7.94
Upside: -
Apr 9, 2020
Maintains: Buy
Price Target: $11 → $6
Current: $411.10
Upside: -98.54%